SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings, Inc. (ALX Oncology or the Company), (Nasdaq: ALXO), is a clinical-stage biotechnology company developing immune-enhancing therapies. System to Cure Cancer and Extend Patients' Lives Today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors will begin granting the directors of ALX Oncology an incentive stock purchase option to purchase an aggregate of 600,000 shares of ALX Oncology common stock to Harish Chantharam, the Company's Chief Financial Officer, while… About starting his work. Mr. Shantharam's incentive stock option is subject to the terms of ALX Oncology Holdings Inc.'s 2025 incentive stock incentive plan. and related forms of agreements, were given as material incentives to Mr. Shantharam to enter into employment with ALX Oncology pursuant to the Nasdaq Stock Exchange. Listing Rule 5635(c)(4).
The incentive stock option has an exercise price of $1.65 per share, which is equal to the closing price of ALX Oncology common stock on the date of grant, and vests as follows: 25% of the shares subject to this incentive stock option. Vests on the first anniversary of January 21, 2025, and an additional forty-one shares of stock subject to the incentive stock option vest monthly thereafter, subject to the employee's continued service.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company that develops therapies that boost the immune system to treat cancer and extend the lives of patients. ALX Oncology's lead therapeutic candidate, evorpacept, has shown potential to serve as a core therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across several ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Contact the company:
Alison Dillon, Chief Business Officer, ALX Oncology
ir@alxoncology.com
Media Contact:
Audra Fries, Sam Brown Company
audrafriis@sambrown.com
(917) 519-9577
Source: ALX Oncology
